MyDrugRef

• Warnings
• Treatments
• Interactions
• Bulletins
• Guidelines
• Drug Monitorings
• Prices

four- to six-week trial of quinine at a dose of 200 to 300 mg at bedtime. Higher doses of quinine are associated with dizziness, visual impairment, tinnitus, gait disturbance, headache and hypersensitivity reactions. Fatal thrombocytopenia has also been reported. At the lower doses used for nocturnal cramps, usually only tinnitus is commonly reported. However, patients need to be counselled about the more serious side effects. Treatment should be interrupted every three months to assess further need

  2 comments so far

Shelly H.

Wednesday 18 August 2010 - 14:05 PM

David, your reference doesn't seem to support your treatment option. I think the reference should be e-therapeutics.
-Shelly

David C.

Tuesday 28 December 2010 - 20:00 PM

From Cochrane Review:
There is moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days in dosages between 200 and 500 mg/day. There is moderate quality evidence that with use up to 60 days, the incidence of serious adverse events is not significantly greater than for placebo in the identified trials. Further research is required on the optimal dose and duration of use, and also on alternative treatments.
http://www.ncbi.nlm.nih.gov/pubmed/21154358?dopt=Abstract

Search Posts

Get RSS Feeds!